Welcome to our dedicated page for Viracta Therapeutics SEC filings (Ticker: VIRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viracta Therapeutics filings document corporate-status disclosures for the company's common stock and public-company reporting profile. The Form 25-NSE filed by Nasdaq records the removal of Viracta's common stock from listing and registration on the Nasdaq Stock Market under Section 12(b) of the Securities Exchange Act of 1934.
For this issuer, the filing record is centered on exchange-listing status, the registered class of securities, and the formal regulatory notice associated with delisting and withdrawal of exchange registration.